Development of odour-based non-invasive diagnostics (NID) for infectious diseases to deliver affordable, accurate and accessible diagnosis

开发基于气味的传染病无创诊断 (NID)，以提供负担得起、准确且易于获得的诊断

• 批准号: 10021980
• 金额: $ 36.6万
• 依托单位: ARCTECH INNOVATION LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10021980
• 关键词: Development; odour; based; non; invasive

There are no changes to the published description, as detailed below:Many infectious diseases cause changes in human body odour, generating a profile that can potentially be used for rapid, low-cost and non-invasive diagnosis. Arctech Innovation is building on early research to create a breakthrough diagnostic platform utilising electronic sensors to accurately detect the unique profiles from infected individuals.This project focuses on prototype diagnostic device development with malaria as an initial proof-of-concept, to validate Arctech Innovation's approach and address a critical need for improved methods of early-stage diagnosis and detecting asymptomatic/mild malaria infections that are frequently undetected or misdiagnosed. It builds on extensive analytical chemistry studies and Arctech Innovation's initial sensor evaluation/assessment, which show feasibility of detecting malaria at an earlier stage than is currently possible and when infection levels are lower.This game-changing solution will deliver wide-ranging socio-economic benefits to globally-disadvantaged groups. Worldwide, there were ~229m malaria cases and ~409,000 deaths during 2019 in 87 countries. Despite previous success, progress against malaria has stalled, and WHO morbidity and mortality reduction targets will be missed whilst the economic direct/indirect costs are vast. Further progress requires addressing key challenges such as improved methods for early-stage diagnosis (2 weeks prior to late-stage diagnosis) and detecting asymptomatic individuals that can still transmit malaria parasites and may account for up to 50% of onward transmission.The malaria diagnostics market (2020 value ~£800m) increasingly demands early diagnosis and surveillance systems in developing countries, representing a significant export opportunity. The wider infectious diseases market is a much larger opportunity thus demonstrating the potential value of our technology.

已发布的描述没有变化，详情如下：许多传染病会导致人体气味发生变化，从而产生可用于快速、低成本和非侵入性诊断的特征。Arctech Innovation 正在建立在早期研究的基础上。创建一个突破性的诊断平台，利用电子传感器准确检测受感染个体的独特特征。该项目侧重于以疟疾为初始概念验证的原型诊断设备开发，以验证 Arctech Innovation 的方法并满足改进的关键需求早期诊断方法它建立在广泛的分析化学研究和 Arctech Innovation 的初始传感器评估/评估的基础上，这表明在比目前更早的阶段和感染水平较低时检测疟疾的可行性。这一改变游戏规则的解决方案将为全球弱势群体带来广泛的社会经济效益。全球范围内约有 2.29 亿疟疾病例。 2019 年，87 个国家约有 409,000 人死亡，但防治疟疾的进展仍然停滞不前，世卫组织将无法实现降低发病率和死亡率的目标，而直接/间接经济成本巨大，需要解决关键挑战，例如改进疟疾防治方法。早期诊断（晚期诊断前 2 周）并检测仍可传播疟疾寄生虫且可能占后续传播比例高达 50% 的无症状个体。疟疾诊断市场（2020 年价值约 8 亿英镑）越来越需要发展中国家的早期诊断和监测系统，这代表着一个重要的出口机会，更广泛的传染病市场是一个更大的机会，从而证明了我们技术的潜在价值。